The Business Standard believes that the partnership to produce biosimilars between Pfizer and Biocon is just one that will start a landslide of partnerships for Big Pharma. They believe that many companies will turn to India for production for vaccines and biosimilars in particular. Biotech drugs resulting in close to $580 million in revenue in just India alone, and fast growth throughout the globe presents opportunities for Pharma companies and biotech producers to partner up and produce viable generics, vaccines and biosimilars. The Business Standard believes that Indian companies that have the potential to benefit the most from this are
Panacea Biotec, Reliance Life Sciences, Bharat Biotech, BV Corp and Serum Institute of India, beside drug majors such as Wockhardt, Dr Reddy's Laboratories, Intas Biopharmaceuticals and Lupin.
|
Share this article with your social network, just click below to share now!
|
|
|
photo credit: @KimTweetsDC For over 20 years we have been working hard on delivering you with first-hand insights into one of the mo...
Last month we blogged about five women to watch in Boston biotech and got an incredible response. In a country where less than five percent...
No comments :
Post a Comment